Wells Fargo analyst Stephen Baxter raised the firm’s price target on BrightSpring Health (BTSG) to $33 from $27 and keeps an Overweight rating on the shares. The firm is updating estimates and price targets in the space ahead of Q3 2025 results. Notability, Wells now assumes extension of enhanced subsidies is likely.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- UnitedHealth (UNH) Divests Home Health and Hospice Assets Worth $146.5M to Pennant
- BrightSpring Health price target raised to $31 from $27.50 at BofA
- BrightSpring Health price target raised to $30 from $25 at Deutsche Bank
- BrightSpring Health Services: Strong Market Position and Growth Potential Justify Buy Rating